The US Food and Drug Administration (FDA) has approved Lynkuet, a once-daily, non-hormonal pill developed by Bayer to treat moderate to severe hot flashes and night sweats in menopausal women. The ...

Inluriyo, an oral estrogen receptor antagonist, significantly reduced disease progression risk in ESR1-mutated metastatic breast cancer, as shown in the EMBER-3 trial. Keytruda Qlex, a subcutaneous ...

Stoboclo and Osenvelt were approved as interchangeable biosimilars for bone loss conditions, potentially reducing costs and increasing access. Darzalex Faspro was approved for high-risk smoldering ...

Gepotidacin, a new oral antibiotic class, was approved for uncomplicated UTIs, showing noninferiority to nitrofurantoin in phase 3 trials. Semaglutide's indications expanded to include cardiovascular ...